Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).

Minang JT, Inglefield JR, Harris AM, Lathey JL, Alleva DG, Sweeney DL, Hopkins RJ, Lacy MJ, Bernton EW.

Vaccine. 2014 Nov 28;32(50):6847-54. doi: 10.1016/j.vaccine.2014.01.096. Epub 2014 Feb 13.

2.

Characterization of the native form of anthrax lethal factor for use in the toxin neutralization assay.

Lu H, Catania J, Baranji K, Feng J, Gu M, Lathey J, Sweeny D, Sanford H, Sapru K, Patamawenu T, Chen JH, Ng A, Fesseha Z, Kluepfel-Stahl S, Minang J, Alleva D.

Clin Vaccine Immunol. 2013 Jul;20(7):986-97. doi: 10.1128/CVI.00046-13. Epub 2013 May 1.

3.

Amelioration of glucose intolerance by the synthetic androstene HE3286: link to inflammatory pathways.

Wang T, Villegas S, Huang Y, White SK, Ahlem C, Lu M, Olefsky JM, Reading C, Frincke JM, Alleva D, Flores-Riveros J.

J Pharmacol Exp Ther. 2010 Apr;333(1):70-80. doi: 10.1124/jpet.109.161182. Epub 2010 Jan 12.

PMID:
20068030
4.

Gene array analysis comparison between rat collagen-induced arthritis and human rheumatoid arthritis.

Soto H, Hevezi P, Roth RB, Pahuja A, Alleva D, Acosta HM, Martinez C, Ortega A, Lopez A, Araiza-Casillas R, Zlotnik A.

Scand J Immunol. 2008 Jul;68(1):43-57. doi: 10.1111/j.1365-3083.2008.02117.x. Epub 2008 May 14.

5.

Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responses.

Pahuja A, Maki RA, Hevezi PA, Chen A, Verge GM, Lechner SM, Roth RB, Zlotnik A, Alleva DG.

Scand J Immunol. 2006 Oct;64(4):361-9.

6.

Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.

Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA.

Scand J Immunol. 2006 Jan;63(1):59-69.

7.

A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells.

Ott TR, Pahuja A, Lio FM, Mistry MS, Gross M, Hudson SC, Wade WS, Simpson PB, Struthers RS, Alleva DG.

J Pharmacol Toxicol Methods. 2005 Mar-Apr;51(2):105-14. Epub 2004 Nov 5.

PMID:
15767203
8.

Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist.

Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM, Gottlieb PA, Wade WS, Kiankarimi M, Schwarz D, Crowe P, Zlotnik A, Alleva DG.

J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71. Epub 2005 Mar 10.

PMID:
15761110
9.

Identification of CC chemokine receptor 7 residues important for receptor activation.

Ott TR, Pahuja A, Nickolls SA, Alleva DG, Struthers RS.

J Biol Chem. 2004 Oct 8;279(41):42383-92. Epub 2004 Jul 28.

10.

Cuttine edge: diabetes-associated quantitative trait locus, Idd4, is responsible for the IL-12p40 overexpression defect in nonobese diabetic (NOD) mice.

Simpson PB, Mistry MS, Maki RA, Yang W, Schwarz DA, Johnson EB, Lio FM, Alleva DG.

J Immunol. 2003 Oct 1;171(7):3333-7.

11.

Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand.

Kim HJ, Antel JP, Duquette P, Alleva DG, Conlon PJ, Bar-Or A.

Clin Immunol. 2002 Aug;104(2):105-14.

PMID:
12165271
12.

Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.

Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, Ling N, Boehme SA, Conlon PJ.

Diabetes. 2002 Jul;51(7):2126-34.

13.
15.

A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin.

Alleva DG, Crowe PD, Jin L, Kwok WW, Ling N, Gottschalk M, Conlon PJ, Gottlieb PA, Putnam AL, Gaur A.

J Clin Invest. 2001 Jan;107(2):173-80.

17.

Radial scar of the breast: radiologic-pathologic correlation in 22 cases.

Alleva DQ, Smetherman DH, Farr GH Jr, Cederbom GJ.

Radiographics. 1999 Oct;19 Spec No:S27-35; discussion S36-7.

PMID:
10517441
19.

Tumor-induced immune dysfunction: the macrophage connection.

Elgert KD, Alleva DG, Mullins DW.

J Leukoc Biol. 1998 Sep;64(3):275-90. Review.

PMID:
9738653
20.
22.
25.

Macrophage priming and activation during fibrosarcoma growth: expression of c-myb, c-myc, c-fos, and c-fms.

Alleva DG, Askew D, Burger CJ, Elgert KD.

Immunol Invest. 1994 Nov;23(6-7):457-72.

PMID:
7851963
27.
29.

Fibrosarcoma-induced increase in macrophage tumor necrosis factor alpha synthesis suppresses T cell responses.

Alleva DG, Askew D, Burger CJ, Elgert KD.

J Leukoc Biol. 1993 Aug;54(2):152-60.

PMID:
8360594
30.

Tumor-induced macrophage tumor necrosis factor-alpha production suppresses autoreactive T cell proliferation.

Alleva DG, Burger CJ, Elgert KD.

Immunobiology. 1993 Aug;188(4-5):430-45.

PMID:
8244447
32.

Supplemental Content

Loading ...
Support Center